Renal Anemia - Pipeline Review, H2 2015

Date: October 30, 2015
Pages: 124
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: R7A05EBBE42EN
Leaflet:

Download PDF Leaflet

Renal Anemia - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Renal Anemia - Pipeline Review, H2 2015’, provides an overview of the Renal Anemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Renal Anemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Renal Anemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Renal Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Renal Anemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Renal Anemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Renal Anemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Renal Anemia Overview
Therapeutics Development
Pipeline Products for Renal Anemia - Overview
Renal Anemia - Therapeutics under Development by Companies
Renal Anemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Renal Anemia - Products under Development by Companies
Renal Anemia - Companies Involved in Therapeutics Development
Acceleron Pharma, Inc.
Akebia Therapeutics, Inc.
Amgen Inc.
Aprogen, Inc.
Bayer AG
BIOCAD
CCM Duopharma Biotech Bhd.
Chong Kun Dang Pharmaceutical Corp.
Daiichi Sankyo Company, Limited
Dong-A Socio Group
Dr. Reddy's Laboratories Limited
Eli Lilly and Company
FibroGen, Inc.
GlaxoSmithKline Plc
Intas Pharmaceuticals Ltd.
Japan Tobacco Inc.
JCR Pharmaceuticals Co., Ltd.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Medgenics Inc.
Myungmoon pharmaceutical Co., Ltd.
Panacea Biotec Limited
Pfizer Inc.
ProMetic Life Sciences Inc.
Sandoz International GmbH
Zydus Cadila Healthcare Limited
Renal Anemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Biologic for Renal Anemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
daprodustat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
darbepoetin alfa (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DS-1093 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EPO-018B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
epoetin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
epoetin alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
epoetin alfa (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FG-2216 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JTZ-951 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDGN-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MMP-0101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
molidustat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PBI-1402 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PEG-EPO - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peg-EPO - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PEG-EPO - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PRS-080 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein for Renal Anemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
roxadustat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit HIF-PH for Renal Anemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sotatercept - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SSS-06 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vadadustat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Renal Anemia - Recent Pipeline Updates
Renal Anemia - Dormant Projects
Renal Anemia - Discontinued Products
Renal Anemia - Product Development Milestones
Featured News & Press Releases
Aug 12, 2015: Nephrology Dialysis Transplantation Reports Phase 2 Data Of Investigational Orally Active Hif-Phi Roxadustat (Fg-4592) Shows Improved Hemoglobin Levels In Non-Dialysis Ckd Subjects With Anemia
Jul 15, 2015: Medgenics Announces First Patient Enrolled in U.S.-Based Phase 2 Clinical Trial of TARGT-EPO for Treatment of Anemia in ESRD Patients Undergoing Peritoneal Dialysis
May 26, 2015: Akebia Therapeutics Announces Presentation of AKB-6548 Phase 2b Data at the 52nd ERA-EDTA Annual Congress
Mar 27, 2015: Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen
Mar 16, 2015: Akebia Announces Presentation of Results from its Phase 2b Study of AKB-6548 in Non-Dialysis Patients with Anemia at WCN
Mar 11, 2015: Bayer to Present Latest Clinical Data On Molidustat
Mar 10, 2015: Akebia Announces Completion of Enrollment in Phase 2 Trial of AKB-6548 in Dialysis Patients with Anemia Related to Chronic Kidney Disease
Oct 15, 2014: Medgenics Reports Positive Initial Clinical Data From Clinical Study Of MDGN-201
Sep 13, 2013: Approval of Additional Indication of Long-Acting Erythropoiesis-Stimulating Agent NESP for Pediatric Patients with renal anemia in Japan
Jul 31, 2013: Astellas and FibroGen Announce the Initiation of a Phase 2 Clinical Study in Japan of ASP1517/FG-4592 for Treatment of Anemia of Chronic Kidney Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Renal Anemia, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd...1)
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd...1)
Products under Development by Companies, H2 2015 (Contd...2)
Renal Anemia - Pipeline by 3SBio Inc., H2 2015
Renal Anemia - Pipeline by Acceleron Pharma, Inc., H2 2015
Renal Anemia - Pipeline by Akebia Therapeutics, Inc., H2 2015
Renal Anemia - Pipeline by Amgen Inc., H2 2015
Renal Anemia - Pipeline by Aprogen, Inc., H2 2015
Renal Anemia - Pipeline by Bayer AG, H2 2015
Renal Anemia - Pipeline by BIOCAD, H2 2015
Renal Anemia - Pipeline by CCM Duopharma Biotech Bhd., H2 2015
Renal Anemia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015
Renal Anemia - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Renal Anemia - Pipeline by Dong-A Socio Group, H2 2015
Renal Anemia - Pipeline by Dr. Reddy's Laboratories Limited, H2 2015
Renal Anemia - Pipeline by Eli Lilly and Company, H2 2015
Renal Anemia - Pipeline by FibroGen, Inc., H2 2015
Renal Anemia - Pipeline by GlaxoSmithKline Plc, H2 2015
Renal Anemia - Pipeline by Intas Pharmaceuticals Ltd., H2 2015
Renal Anemia - Pipeline by Japan Tobacco Inc., H2 2015
Renal Anemia - Pipeline by JCR Pharmaceuticals Co., Ltd., H2 2015
Renal Anemia - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H2 2015
Renal Anemia - Pipeline by Medgenics Inc., H2 2015
Renal Anemia - Pipeline by Myungmoon pharmaceutical Co.,Ltd., H2 2015
Renal Anemia - Pipeline by Panacea Biotec Limited, H2 2015
Renal Anemia - Pipeline by Pfizer Inc., H2 2015
Renal Anemia - Pipeline by ProMetic Life Sciences Inc., H2 2015
Renal Anemia - Pipeline by Sandoz International GmbH, H2 2015
Renal Anemia - Pipeline by Zydus Cadila Healthcare Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Renal Anemia Therapeutics - Recent Pipeline Updates, H2 2015
Renal Anemia - Dormant Projects, H2 2015
Renal Anemia - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Renal Anemia, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Mechanism of Actions, H2 2015
Number of Products by Stage and Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015
Skip to top


Iron Deficiency Anemia - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 68 pages
Chemotherapy Induced Anemia - Pipeline Review, H2 2015 US$ 1,600.00 Sep, 2015 · 67 pages

Ask Your Question

Renal Anemia - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: